In an attempt to provide a new avenue for MPM treatment, we and others8–10 have recently investigated a more generic approach of targeting the BCL-2 pro-survival proteins (i.e., BCL-2, BCL-XL, BCL-W, MCL-1 and BFL-1) that frequently have deregulated expression in cancer cells, leading to increased tumor cell survival and treatment resistance11. Here, BCL2 is linked to cancer.